HCA Healthcare, Inc. (HCA) Stock Analysis

44.0/100
Sell Not Halal Healthcare
Price $499.05
Market Cap $104.25B
52-Week Change +5.44%

Is HCA a good investment?

HCA Healthcare, Inc. (HCA) has a Plutrex AI rating of 44.0/100 as of November 11, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: FCF of $5.973B (~5.4% yield) provides exceptional capital allocation capacity — funds debt service, buybacks, and acquisitions without equity dilution; this remains HCA's most durable competitive moat and distinguishes it from smaller, capital-constrained peers. Main concern: VALUATION DETERIORATION: Stock at $504.42 is now 6.1% ABOVE analyst consensus of $475.40 (inverted from prior cycle's 9.2% discount) — negative risk/reward with PEG rising from 1.93x to 2.26x (+17%), P/E rising from 15.06x to 16.71x (+11%), and revenue growth collapsing from 8.7% to 3.6% (-58.6%) simultaneously; at current price, upside to consensus is -5.8% and downside to fair value ($335-$370) is -27% to -34%.

Investment Summary

HCA Healthcare trades at $504.42, now 6.1% ABOVE the reduced analyst consensus target of $475.40 (down from $495.50 prior cycle) — a materially worse risk/reward profile than 14 days ago when the stock was at $449.96 and 9.2% BELOW consensus. The stock has surged +12.1% while the analyst target was CUT -4.1%, creating a widening dislocation. Fundamentals: P/E of 16.71x (up from 15.06x prior), PEG of 2.26 (up from 1.93x prior, well above fair value threshold of 1.0). Forward EPS growth of only 4.1% (next year) and 7.4% (5-year) remain deeply below the industry average of 12.63% and 13.40% respectively. FCF of $5.973B (~5.4% yield) remains the crown jewel. Net margin 8.61% beats industry 6.66% by +295bps. However, revenue growth of 3.6% vs. industry 6.42% confirms structural growth lag. The Pomerantz Law Firm investigation (appearing for the fourth consecutive cycle in headlines: 'INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HCA') remains unresolved and represents a binary legal overhang. At current price, upside to analyst consensus is NEGATIVE (-5.8%) and the stock is priced as if all concerns are resolved — they are not.

Key Strengths

Key Concerns

Plutrex 10-Factor AI Breakdown

Financial Health
60/100
Growth Potential
20/100
Valuation
25/100
Profitability
72/100
Debt Management
50/100
Analyst Sentiment
40/100
Technical Momentum
65/100
Insider Confidence
44/100
News Sentiment
52/100

Fundamental Analysis

P/E of 16.71x vs. industry average ~15.69x — HCA trades at a 6.5% PE premium to peers despite being a growth laggard. PEG of 2.26 vs. industry average 2.70 — HCA is relatively better than sector peers on PEG, but both are stretched; in absolute terms, PEG of 2.26 against 7.4% 5-year growth implies fair P/E ~7.4-10x and intrinsic value of $220-$300 (generous case to $335-$370 at 1.5x PEG). Operating margin 14.83% beats industry 12.76% (+16.2% premium) — genuine scale advantage. Net margin 8.61% beats industry 6.66% (+29.3%) — best-in-class conversion. Gross margin 15.31% trails industry 19.01% (-19.5%) — reflects high direct care costs. FCF of $5.973B is exceptional (~5.4% yield at current $110B market cap). Revenue growth 3.6% vs. industry 6.42% — peers growing topline nearly 2x faster. Next-year EPS growth 4.1% vs. industry 12.63% — HCA growing EPS at one-third the peer rate. Total cash $1.019B is thin, but FCF generation is the real liquidity backstop. Negative book equity (D/E N/A) reflects aggressive buybacks — not distress, but masks substantial debt ($30B+ estimated) vs. industry average D/E of 1.10. Analyst consensus target CUT from $495.50 to $475.40 (-$20.10, -4.1%) while stock ROSE $54.46 (+12.1%) — 16.2 percentage point adverse divergence in 14 days.

News Sentiment

HCA Healthcare is facing a complicated picture heading into late 2026, with a mix of clinical recognition and legal uncertainty swirling around America's largest hospital operator. On the bright side, the company just earned a remarkable distinction: 102 HCA hospitals were recognized by Healthgrades for excellence in specialty care — more than any other health system in the country. That's the kind of third-party validation that helps HCA negotiate better contracts with insurers and attract high-value patients. Some analysts are pointing to 'Earnings Growth & Price Strength' as reasons to watch the stock closely, and there's even positive buzz around 'Hospital Stocks Soared as Democrats Took Congress,' suggesting a favorable policy backdrop. But here's the dark cloud: Pomerantz Law Firm has now issued multiple investor alerts investigating potential securities violations at HCA — a headline that has appeared repeatedly without resolution. For everyday investors, that's a flashing yellow light. The firm investigates claims on behalf of shareholders who may have been harmed, and while these investigations don't always result in legal action, the prolonged uncertainty is a real concern. Meanwhile, long-term investors are being told to focus on HCA's fundamental strengths — but with the stock trading above where even Wall Street analysts think it's worth, patience and caution seem to be the smarter play right now.

Risk Assessment

PRIMARY RISK (CURRENT PRICE): At $504.42, HCA is 6.1% above analyst consensus ($475.40), creating immediate downside to consensus alone of -$29/share (-5.8%). Beyond consensus, PEG-based fair value of $335-$370 represents -27% to -34% downside if growth deceleration is fully priced in. The Pomerantz investigation adds binary legal risk — any adverse finding, securities class action certification, or settlement announcement could accelerate the decline. SECONDARY RISK: Revenue growth falling from 8.7% to 3.6% (-58.6% deceleration) in one cycle suggests payer mix headwinds (the $400M coverage gap from prior cycle) may be intensifying. MITIGATION: If forced to hold, FCF of $5.973B provides a floor — management can accelerate buybacks at lower prices. Stop-loss at $415 (for a re-entry scenario) limits downside to 6.7% from the $445 entry midpoint. OPPORTUNITY RISK (DO NOT ENTER AT CURRENT PRICE): Upside to analyst consensus from $504.42 is -5.8% — there is no margin of safety at current price. Wait for $435-$455 zone where P/E approaches 13-13.6x and PEG approaches 1.75-1.84x, more consistent with a growth laggard growing EPS at half the industry rate.

Related Halal Stocks

Related Stocks

Frequently Asked Questions

Is HCA a halal stock?

No, HCA Healthcare, Inc. (HCA) is currently not classified as halal by AAOIFI criteria.

What is Plutrex's AI rating for HCA?

HCA Healthcare, Inc. (HCA) has a Plutrex AI rating of 44.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.

Is HCA a good investment?

According to Plutrex AI, HCA has a Sell rating (44.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.

How can I invest in HCA?

US stocks like HCA can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.

What are the main risks of investing in HCA?

Plutrex AI identifies the main risks for HCA by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.

Chat with ElBarake AI about HCA

Ask anything about this stock and get an instant AI-powered answer — free, no signup required.

Open HCA in ElBarake